おすすめの製品
詳細
eMTG (Enhanced Microbial Transglutaminase) is an enzyme that catalyzes the formation of new isopeptide bonds between the primary amine of a drug linker and glutamine residues at position Q295 of IgG-type antibodies to produce site-specifically conjugated antibody-drug conjugates (ADCs).
アプリケーション
Site-specific conjugation is increasingly used in drug research, development, and manufacturing to produce ADCs and bioconjugates with defined drug-to-antibody ratios (DAR) since the resulting homogeneity improves safety and efficacy. Transglutaminase (TG)-mediated bioconjugation is a promising means of conjugating drug linkers specifically to the Q295 position of antibodies. However, its use traditionally requires antibody or glycan engineering since the adjacent glycosylation at N297 interferes with the TG reaction. If you are interested in trying eMTG to make therapeutic ADCs but do not currently have the conjugation setup/expertise, please consider ADC Express ™Service for pre-clinical lead candidate selection.
特徴および利点
• Increased efficiency - with one-step bioconjugation for ADCs
• Glycosylation-tolerant - no need to remove glycosylation allowing for a preserved glycan on the antibody conjugate product
• Built for purpose - eMTG has been designed for producing ADCs and bioconjugates
• For higher-grade quality suitable for cGMP manufacturing of ADCs, please reach out using this form https://www.sigmaaldrich.com/US/en/services/contract-manufacturing/adc-bioconjugation/adc-bioconjugation-request-information with eMTG selected.
• Glycosylation-tolerant - no need to remove glycosylation allowing for a preserved glycan on the antibody conjugate product
• Built for purpose - eMTG has been designed for producing ADCs and bioconjugates
• For higher-grade quality suitable for cGMP manufacturing of ADCs, please reach out using this form https://www.sigmaaldrich.com/US/en/services/contract-manufacturing/adc-bioconjugation/adc-bioconjugation-request-information with eMTG selected.
単位の定義
One unit will catalyze the formation of 1.0 micromole of hydroxamate per minute from N Z GLN-GLY and hydroxylamine at pH 6.0 at 37°C.
法的情報
ADC EXPRESS is a trademark of Merck KGaA, Darmstadt, Germany
シグナルワード
Danger
危険有害性情報
危険有害性の分類
Resp. Sens. 1
保管分類コード
11 - Combustible Solids
WGK
WGK 1
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
SAE0217-250UN:
SAE0217-BULK:
SAE0217-VAR:
SAE0217-50UN:
SAE0217-2000UN:
最新バージョンのいずれかを選択してください：
試験成績書（COA）
Lot/Batch Number
Stephan Dickgiesser et al.
Methods in molecular biology (Clifton, N.J.), 2012, 135-149 (2019-06-05)
Antibody-drug conjugates (ADCs) are a relatively young class of cancer therapeutics that combine the superior selectivity of monoclonal antibodies (mAbs) with the high potency of cytotoxic agents. In the first generation of ADCs, the toxic payload is attached to the
Stephan Dickgiesser et al.
Bioconjugate chemistry, 31(4), 1070-1076 (2020-03-07)
Site-specific bioconjugation technologies are frequently employed to generate homogeneous antibody-drug conjugates (ADCs) and are generally considered superior to stochastic approaches like lysine coupling. However, most of the technologies developed so far require undesired manipulation of the antibody sequence or its
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）